BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Braveheart Bio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 8, 2026
$19.21+0.50 (+2.67%)
Close on Oct 19, 2026
- Market cap
- $142.19M
- P/E (TTM)
- –
- Dividend yield
- –
Braveheart Bio statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Braveheart Bio | Industry median |
|---|---|---|
| Market Cap | $144.77M | $166.30M |
| Enterprise Value | $21.94M | $88.19M |
Balance sheet
| Measure | Braveheart Bio | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $122.83M | $61.43M |
| Net Cash (Debt) | $122.83M | $15.35M |
| Net Cash Per Share | $16.30 | $0.66 |
| Equity (Book Value) | -$95.91M | $49.09M |
| Book Value Per Share | -$12.73 | $1.37 |
| Tangible Book Value | -$95.91M | $23.52M |
| Working Capital | $114.39M | $76.81M |
Financial position
| Measure | Braveheart Bio | Industry median |
|---|---|---|
| Current Ratio | 13.63 | 3.34 |
| Quick Ratio | 13.56 | 2.44 |
Shares
| Measure | Braveheart Bio | Industry median |
|---|---|---|
| Shares Outstanding | 7,535,990 | 58,127,000 |
Scores
| Measure | Braveheart Bio | Industry median |
|---|---|---|
| Altman Z-Score | 9.32 | -0.22 |
Calculated by StockData from Braveheart Bio's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.